KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Receivables (2018 - 2025)

Historic Receivables for Adaptive Biotechnologies (ADPT) over the last 8 years, with Q3 2025 value amounting to $46.3 million.

  • Adaptive Biotechnologies' Receivables rose 998.96% to $46.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $46.3 million, marking a year-over-year increase of 998.96%. This contributed to the annual value of $43.0 million for FY2024, which is 1042.37% up from last year.
  • Latest data reveals that Adaptive Biotechnologies reported Receivables of $46.3 million as of Q3 2025, which was up 998.96% from $45.6 million recorded in Q2 2025.
  • Over the past 5 years, Adaptive Biotechnologies' Receivables peaked at $46.3 million during Q3 2025, and registered a low of $16.5 million during Q2 2021.
  • Its 5-year average for Receivables is $33.2 million, with a median of $32.4 million in 2023.
  • In the last 5 years, Adaptive Biotechnologies' Receivables skyrocketed by 11722.05% in 2022 and then tumbled by 462.1% in 2023.
  • Over the past 5 years, Adaptive Biotechnologies' Receivables (Quarter) stood at $18.8 million in 2021, then skyrocketed by 117.22% to $40.9 million in 2022, then fell by 4.62% to $39.0 million in 2023, then rose by 10.42% to $43.0 million in 2024, then increased by 7.65% to $46.3 million in 2025.
  • Its last three reported values are $46.3 million in Q3 2025, $45.6 million for Q2 2025, and $45.1 million during Q1 2025.